Pipeline
Advancing novel precision therapeutics for serious cardiovascular diseases
Cardiovascular
Program
Indications
| Preclinical | Phase 1 | Phase 2 | Pivotal / Phase 3 |
Regulatory Submission |
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator for the treatment of HCM.
EDG-15400 is a novel oral, selective, cardiac sarcomere modulator, for the treatment of HFpEF and other diseases of diastolic dysfunction
EDG-003
Undisclosed Target
Cardiometabolic
Preclinical
Is a clinical trial right for you?
We are currently conducting clinical trials in severe cardiovascular diseases.
